When I heard that I thought it mostly referred to the centers in the first instance. With no standard of care these centers have been trying their best to get patients care when this condition develops. They now want to be able to prescribe it without going through the EAP. That to me is positive for prescriptions being written.
The second part refers to payers. Even though there are over 1000 health insurance companies in the USA, a majority of people are covered by small number of 'national' carriers. I think Meso and their reps have been reaching out to these larger insurance companies to sell them on their idea of pricing. It sounds like there was also some discussion about development costs and the need to recover some of that through pricing. Such a discussion might seem strange to some, but everyone understands that a company must recover some costs for the development of a treatment.
With virtually every new product launch, whether that be drugs or tech, there is some element of marketing. In the case of drugs that marketing is aimed at about three groups - the patients and their doctors, the payers and any intermediaries such as PBMs that might be involved. It sounds like the doctors are on board - they are the smallest group and are familiar with the product. Marketing to the payers is all about making them aware of the benefits. Most insurance companies aren't aware of the system costs related to GVHD, and so Meso and their reps would need to bring this to their attention and share the news of approval.
MSB Price at posting:
$2.52 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)